Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Canaglifozin reduced risk of cardiovascular death and hospitalizations due to heart failure by 31%.
Read More »Canagliflozin Effects on Heart Failure and Cardiovascular Death
Canagliflozin Linked to Improved Anemia in Patients with Diabetes and Renal Disease
SGLT-2 inhibitors show additional benefits besides lowering blood glucose.
Read More »Impact of Sotagliflozin Added to Insulin
What is the impact of adjunctive sotagliflozin to insulin therapy on diabetes distress and treatment satisfaction in patients with type 1 diabetes?
Read More »Left Ventricular Mass Reduction and Empagliflozin
Empagliflozin significantly lowered LVMi, systolic blood pressure, and diastolic blood pressure in patients with CAD and type 2 diabetes.
Read More »Empagliflozin Benefit in Heart Failure, With or Without Diabetes
Studies of empagliflozin and dapagliflozin have shown to reduce cardiovascular risk, indicating a class effect for heart failure patients.
Read More »Using SGLT-2 Inhibitors to Significantly Reduce AFib
Diabetes causes metabolic changes that promote oxidative stress within the heart, resulting in changes that can impede its electrical signaling.
Read More »Analysis of Sotagliflozin’s Effect on Cardiorenal Factors for Type 1 Patients
Can use of the sodium-glucose cotransporter 1 and sodium-glucose cotransporter 2 dual inhibitor in patients with type 1 diabetes preserve kidney function?
Read More »The Role of Dapagliflozin in Patients with Type 2 Diabetes and Atrial Fibrillation
A post hoc analysis of the DECLARE-TIMI 58 trial may provide a new compelling indication for dapagliflozin.
Read More »Real-World Data on the Benefit of Sodium Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Risk
SGLT2 inhibitors compared to DPP-4 inhibitors: which showed a favorable effect on MACE?
Read More »The Impact of SGLT2 Inhibitors on All-Cause Mortality
Examining the evidence to date on whether sodium-glucose transporter 2 inhibitors reduce mortality.
Read More »